Avid Bioservices, Inc. provided revenue guidance for the fiscal 2023. For the revenue the company expects revenue of $140 million to $145 million, a 17-21% increase over fiscal 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.97 USD | -1.48% | -8.81% | +22.62% |
30/04 | RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating | MT |
29/04 | Transcript : Avid Bioservices, Inc., Q3 2024 Earnings Call, Apr 29, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.62% | 51Cr | |
-1.62% | 9.09TCr | |
-1.05% | 3.9TCr | |
-11.20% | 3.35TCr | |
+63.05% | 2.64TCr | |
-20.75% | 1.45TCr | |
-6.35% | 1.32TCr | |
-11.42% | 1.17TCr | |
-47.67% | 1.06TCr | |
+6.52% | 923.36Cr |
- Stock Market
- Equities
- CDMO Stock
- News Avid Bioservices, Inc.
- Avid Bioservices, Inc. Provides Revenue Guidance for the Fiscal 2023